What the Research Actually Says About Kratom and Heart Health

Kratom and cardiovascular safety is one of the more contentious topics in the current debate over the plant. News stories describe cardiac arrests and dangerous heart rhythms, while a large population of regular users reports no cardiac symptoms at all. The truth sits between those extremes: the science is still thin, weighted heavily toward individual case reports rather than controlled trials, and the risk picture depends far more on dose, existing health conditions, and other substances in someone’s system than on kratom alone. Below is a look at the cardiovascular evidence published through early 2026.

The strongest controlled data available — including an FDA-registered trial by Tanna and colleagues (2022) — found no serious cardiac events at ordinary doses (roughly 2 to 6 grams) in healthy participants. The alarming case reports that do exist, involving QT prolongation, Brugada-pattern ECGs, or right ventricular dysfunction, almost always trace back to extreme daily intake (15 to 100 grams), combined drug use, or a heart condition the person already had. The main way kratom affects the cardiovascular system is through alpha-1 adrenergic receptor activation, which produces a temporary rise in heart rate and blood pressure at stimulant-like doses — not direct damage to heart tissue. For most people, the bigger practical concern isn’t cardiotoxicity itself but kratom’s inhibition of the CYP2D6 and CYP3A4 liver enzymes, which can push blood levels of heart medications (beta-blockers, calcium channel blockers, antiarrhythmics) higher than intended. Anyone with heart disease, an arrhythmia, or a cardiac prescription should talk to a cardiologist before trying kratom. [1]

What kinds of cardiovascular effects has research documented?

Studies on kratom and the heart fall into roughly five categories, each with its own strengths and blind spots. Clinical trials offer the most reliable data but remain few and small. Case reports capture real adverse events, yet they can’t prove kratom caused them, and they overwhelmingly describe severe, worst-case scenarios rather than typical use.

Reported Effects, How Often They Show Up, and Context

Effect	Frequency in Data	Context
Fast heart rate	Most common (~18% in poison control data)	Usually temporary; linked to adrenergic activity at stimulant doses
High blood pressure	Second most common (~11.7%)	Usually temporary; tied to stimulant-range dosing
QTc prolongation	Seen in high-dose or chronic users	Dose-dependent, and appears to reverse after stopping [4]
Brugada-pattern ECG	Rare, in case reports only	Tied to extreme chronic use (~84–100 g/day); resolved after stopping [4]
Cardiac arrest	Rare, in case reports only	Nearly always involves other drugs or an underlying heart condition [5]
Right ventricular dysfunction	One reported case	Fully reversed after four weeks off kratom (95 mmHg down to 26 mmHg) [6]
Low blood pressure	Reported at higher doses	Consistent with opioid-like effects at sedative-range doses [3]

A 2025 review in Frontiers in Pharmacology by Smallets and colleagues examined 95 patients from published case reports and concluded there wasn’t enough evidence to say kratom by itself raises the risk of severe acute health problems. Other substances were present in 32 of the 35 fatal cases reviewed — a pattern the authors called statistically significant (p = 0.0002). [2]

What have clinical trials found?

The best-controlled cardiovascular data comes from a 2022 pharmacokinetic trial led by Tanna and colleagues, registered with the FDA (NCT04392011) and run through Washington State University’s Clinical Research Unit. Healthy adults received a single 2-gram dose of kratom tea, and researchers tracked their vital signs for 120 hours afterward. [1]

Key Details from the Tanna et al. (2022) Trial

Parameter	Result
Study design	Open-label, single dose, FDA IND #145002 (NCT04392011)
Participants	7 enrolled (3 male, 4 female); 5 completed (ages 26–40)
Dose	2 g kratom powder as tea (about 39 mg mitragynine)
Monitoring	120 hours — blood pressure, pulse, oxygen saturation
Serious cardiac events	None
Mitragynine peak concentration	81.9 nM median, reached around 1 hour
Mitragynine half-life	45.3 hours — longer than earlier estimates of ~24 hours
Enzyme inhibition finding	Midazolam exposure rose 40%, confirming CYP3A4 inhibition in living subjects

That 45.3-hour half-life matters for anyone using kratom daily. At typical dosing intervals, mitragynine builds up toward a steady-state level well above what a single dose produces — meaning the concentrations measured in this trial likely understate what regular users actually carry in their system. [1]

A separate single-ascending-dose pilot study, cited in the Smallets 2025 review, reported no adverse cardiovascular effects up to 12 grams. [2] All of these controlled studies share the same limits: small groups, healthy participants only, and short observation windows. They can’t tell us much about chronic use or people with existing heart disease. But within those limits, they consistently show minimal cardiovascular disturbance from typical doses in healthy adults.

How does kratom’s chemistry act on the cardiovascular system?

To understand kratom’s effect on the heart, it helps to look at the receptors its alkaloids interact with.

Adrenergic Activation

Mitragynine binds to alpha-1 adrenergic receptors on the smooth muscle lining blood vessels, causing them to constrict. [3] That’s the mechanism behind the mild, temporary rise in blood pressure and heart rate seen at stimulant-range doses — similar in kind to what caffeine or other mild stimulants produce. Alpha-2 receptor activity also plays a role in the stimulating effects felt at lower doses.

Opioid Receptor Effects at Higher Doses

As the dose climbs, mu-opioid receptor activity starts to dominate the picture. This flips kratom’s cardiovascular profile from stimulant-like to opioid-like: blood pressure can drop, heart rate can slow, and at very high doses, breathing can become suppressed — all standard effects of opioid receptor activation. [3]

Effects on Heart Cell Ion Channels

Lab studies using human stem-cell-derived heart cells found that mitragynine and related alkaloids interfere with calcium channels in cardiac tissue. [8] This offers a partial explanation for the QT prolongation seen in some high-dose cases, since ion channel disruption directly affects the heart’s electrical timing.

Dose Determines the Effect

Kratom’s cardiovascular impact shifts with dose, moving through roughly three phases: [3]

• Low doses (1–5 g): Mild stimulant effect — slight, temporary increases in heart rate and blood pressure from adrenergic activity
• Moderate to high doses (5–15 g): Opioid effects take over — blood pressure may drop, and the stimulant effect fades
• Very high or chronic doses (over 15 g): Meaningful risk of QT prolongation and other electrical disturbances increases

Can kratom prolong the QT interval?

Yes. Dose-dependent QT prolongation is among the best-documented electrical effects of kratom on the heart, though it shows up almost exclusively at extreme doses or alongside other drugs, not with ordinary use. Three lines of evidence point in the same direction.

Lab studies on heart cells. Using human stem-cell-derived cardiomyocytes, researchers found that mitragynine and several related alkaloids inhibit the same potassium channel (the delayed rectifier current) implicated in drug-induced QT prolongation generally. [8] A 2021 review in Frontiers in Pharmacology, synthesizing a decade of cardiac pharmacology and case data, concluded that QT prolongation at high doses fits kratom’s broader multi-channel profile rather than standing out as a fluke. [9]

Measured QT values in case reports. In the Holton (2024) Brugada case, a 25-year-old man consuming an estimated 84 to 100 grams daily showed a QTc of 654 milliseconds at presentation — roughly 15 to 20 times a typical daily amount. [4] A 2025 report in JACC Case Reports documented both a reversible Brugada pattern and QT prolongation in the same patient, with both resolving after he stopped using kratom — supporting the idea that these are drug effects rather than coincidental findings. [10]

What this means practically. Healthy adults taking ordinary doses (1 to 5 grams) without other QT-prolonging drugs are very unlikely to see meaningful changes in their QT interval. The real risk concentrates in three groups: chronic, very-high-dose users; people taking other QT-prolonging medications (certain antiarrhythmics, antipsychotics, macrolide antibiotics, methadone); and people with congenital long QT syndrome, whose baseline electrical margin is already narrow. If you know or suspect you have long QT syndrome, treat that as a real reason to avoid kratom, not a minor caveat.

What do recent case reports show?

Case reports drive most of the concern around kratom and heart health. It’s worth remembering what they can and can’t tell us — they document real adverse events, but they can’t prove kratom caused them, and they lean heavily toward severe outcomes involving multiple substances. [2]

Brugada pattern — Holton et al. (2024), Cureus. A 25-year-old man who had consumed an estimated 84 to 100 grams of kratom daily for four years arrived with a QTc of 654 ms and a type 1 Brugada ECG pattern. After he stopped using kratom, the ECG abnormalities gradually resolved. [4] That dose is roughly 15 to 20 times what a typical user consumes.

Ventricular fibrillation — Dodulík et al. (2024), European Heart Journal Case Reports. A teenager went into ventricular fibrillation during football practice after using kratom along with caffeine and energy products. Heavy exertion combined with multiple stimulants is already known to trigger cardiac events, which makes it hard to pin the cause on kratom specifically. [5]

Right ventricular dysfunction — Alameh et al. (2025), JACC Case Reports. A 24-year-old daily kratom user developed high-output heart failure with severe pulmonary hypertension (right ventricular systolic pressure of 95 mmHg). Four weeks after stopping kratom, an echocardiogram showed the pressure had returned to normal (26 mmHg). [6] The speed and completeness of that recovery stands out.

Brugada syndrome unmasked — Matthews et al. (2026), JACC Case Reports. A young man with no known structural heart disease suffered cardiac arrest associated with kratom use. The authors suggest kratom may reveal a latent electrical abnormality rather than cause new structural damage. [7]

What These Cases Have in Common

A few patterns run through nearly all of the serious case reports:

1. The doses involved are extreme, far above what typical users take
2. Other drugs are present in most of the serious cases (32 of 35 deaths in the Smallets review)
3. Cardiac abnormalities tend to reverse once the person stops using kratom
4. The pattern often looks like an existing condition being revealed, not a new one being created
5. Young men show up disproportionately in these reports

Is kratom-linked Brugada syndrome a real emerging concern?

Between 2024 and 2026, several peer-reviewed case reports described Brugada-pattern ECG findings occurring around the same time as kratom use — enough cases now that it’s hard to call each one a coincidence. The pattern still appears rare relative to the overall population of kratom users, but it’s consistent enough that clinicians and heavy users should be aware of it.

Documented cases in the peer-reviewed literature include:

• Holton et al. (2024) — Type 1 Brugada pattern with a QTc of 654 ms in a chronic, very-high-dose user; reversed after stopping [4]
• Matthews et al. (2026) — Cardiac arrest in a young man, with kratom implicated in revealing a latent electrical abnormality [7]
• Miller et al. (2025) — Reversible Brugada pattern and QT prolongation, both normalizing after cessation [10]
• Abubaker et al. (2025) — Chronic kratom use identified as the trigger for acquired Brugada syndrome [11]
• Al-Harbi & Singh (2026) — A Brugada phenocopy brought on by kratom overdose [12]

What connects these cases. Every one involves either very high doses, long-term heavy use, or an acute overdose — not ordinary consumption. Several show the Brugada pattern fully reversing after the person stopped. Most involve young men, which lines up with what’s already known about who develops native Brugada syndrome. None of the reports describe kratom causing lasting structural heart disease; the consistent picture is one of electrical disruption or an underlying vulnerability being exposed.

What these cases don’t establish. Case reports can’t tell us how common this is. There’s no reliable denominator — no way to calculate risk per million users — so no one can responsibly put a number on the odds. Still, seeing the same temporal link between kratom and Brugada findings show up across independent research teams, different journals, and different countries is the kind of pattern that warrants continued monitoring. Anyone with a family history of sudden cardiac death or unexplained fainting should treat kratom with more caution than the average user — getting a baseline ECG before use is a reasonable step for that group.

Who has a higher cardiovascular risk from kratom?

Risk isn’t uniform. It depends heavily on a person’s existing health, what else they’re taking, and how much and how often they use kratom.

Risk Factors and Why They Matter

Risk Factor	Risk Level	Why
Existing heart disease or arrhythmia	High	Adrenergic activity may worsen arrhythmias, high blood pressure, or heart failure
Using stimulants at the same time (caffeine, amphetamines)	High	Effects add up; the VF case report involved kratom, caffeine, and exercise together [5]
Taking heart drugs metabolized by CYP2D6/CYP3A4	High	Enzyme inhibition can raise beta-blocker, calcium channel blocker, or antiarrhythmic levels to toxic ranges [1]
Latent Brugada syndrome or channelopathy	High	Kratom may reveal a pre-existing electrical abnormality [7]
Very high chronic doses (over 15 g/day)	Moderate to high	QT prolongation is dose-dependent; toxicity tracks with mitragynine blood levels
Using CBD alongside kratom	Moderate	CBD raises mitragynine exposure roughly 2.8-fold through enzyme inhibition [1]
Using opioids or benzodiazepines alongside kratom	High	Effects on breathing and the central nervous system add up; present in most kratom-linked deaths
Healthy adult, low-to-moderate dose, no medications	Low	Trial data (Tanna 2022) shows good tolerability with no cardiac events at 2 g [1]

Drug Interactions: A Bigger Concern Than Direct Toxicity

For people already on cardiovascular medication, the biggest cardiovascular risk from kratom isn’t a direct effect on the heart — it’s the way kratom inhibits the CYP3A4 and CYP2D6 enzymes that break down many heart drugs. [1] Affected drug classes include:

• Beta-blockers (metoprolol, carvedilol): elevated levels can cause dangerously slow heart rate
• Calcium channel blockers (diltiazem, verapamil, amlodipine): elevated levels can cause low blood pressure or arrhythmia
• Antiarrhythmics (amiodarone, flecainide): these already have a narrow safety margin, so even small increases can become toxic
• Statins (atorvastatin, simvastatin): elevated levels raise the risk of muscle damage

Practical guidance for heart-conscious users

If you have no known heart condition

• Start low (1 to 3 grams) and pay attention to how your body responds before increasing the dose
• Don’t pair kratom with stimulants, including large amounts of caffeine or energy drinks
• Don’t combine kratom with opioids, benzodiazepines, or alcohol — the combined depressant effect on breathing and the CNS is dangerous
• Skip intense exercise right after taking kratom, especially if you’ve also used a stimulant
• Watch for warning signs — a racing heart that won’t settle, chest pain, or palpitations mean stop and see a doctor
• Stay hydrated, since dehydration adds to cardiovascular strain

If you have an existing heart condition

• Talk to your cardiologist before using kratom at all — this isn’t optional
• Kratom’s adrenergic effects can aggravate high blood pressure, arrhythmias, or heart failure
• Tell any doctor prescribing heart medication that you use kratom — enzyme interactions can push drug levels into toxic territory
• Remember that kratom doesn’t show up on standard drug tests, so your care team can only account for it if you tell them directly

For everyone

• Buy from sources with AKA GMP certification and lab testing — contamination or adulteration adds unpredictable risk on top of kratom’s own effects
• Keep in mind that long-term cardiovascular safety data simply doesn’t exist yet
• Use the lowest effective dose and frequency — with a 45-hour half-life, daily use builds up substantially in your system over time